BOULDER, CO--(Marketwire - April 08, 2009) - Encision Inc. ("Encision") (OTCBB: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, is pleased to announce that it has entered into a non-exclusive manufacturing, supply and licensing agreement with Intuitive Surgical Inc. ("Intuitive Surgical") (NASDAQ: ISRG) for the purchase and use of Encision's patented AEM® technology with Intuitive Surgical's da Vinci® Surgical Systems. Encision's agreement with Intuitive Surgical will allow Encision access beyond conventional laparoscopy to the next generation of minimally invasive surgery.
"We are excited about partnering with Intuitive Surgical, the world's leader in surgical robotics," stated Jack Serino, President and CEO of Encision Inc. "Prior to the agreement, Encision was focused on conventional laparoscopic surgery. Now, we can expand our technology into the rapidly growing market segment of laparoscopic robotic surgery."
About Encision:
Encision designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery. For more information, visit Encision's web site at www.encision.com.
In accordance with the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, the Company notes that statements in this
press release and elsewhere that look forward in time, which include
everything other than historical information, involve risks and
uncertainties that may cause actual results to differ materially from those
indicated by the forward-looking statements. Factors that could cause the
Company's actual results to differ materially include, among others, its
ability to increase net sales through the Company's distribution channels,
insufficient quantity of new account conversions, insufficient cash to fund
operations, scale up production to meet delivery obligations, delay in
developing new products and receiving FDA approval for such new products
and other factors discussed in the Company's filings with the Securities
and Exchange Commission. Readers are encouraged to review the risk factors
and other disclosures appearing in our filings with the Securities and
Exchange Commission. We do not undertake any obligation to update publicly
any forward-looking statements, whether as a result of the receipt of new
information, future events, or otherwise.
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati:
